Codification of Medicare Drug Price Negotiation: What the Final Rule Means for Manufacturers

Author: Rosalie Hoyle, PhD, Engagement Manager, Strategic Consulting

On November 5, the Centers for Medicare & Medicaid Services (CMS) released the Final Rule for Medicare Drug Price Negotiation Program, which takes effect on December 5, 2026, and applies beginning with Initial Price Applicability Year (IPAY) 2029. The Final Rule codifies the Medicare Drug Price Negotiation Program as CMS transitions from annual guidance documents to formal rulemaking. While preserving many of the program's core policies, the rule also clarifies existing requirements and introduces new provisions. Most importantly, it converts CMS's first three years of negotiation guidance into a durable regulatory framework that is expected to govern the program for years to come.

What Is Staying the Same?

By codifying the Medicare Drug Price Negotiation Program, CMS reduces the year-to-year uncertainty associated with a process that has evolved significantly since its inception. Manufacturers can now expect greater consistency beginning with IPAY 2029.

The Final Rule largely maintains policies previously established in IPAY 2028 guidance, including:

• Selection eligibility and ineligibility requirements
• Manufacturer participation requirements
  
• Negotiation factors and processes
• Renegotiation requirements

For manufacturers, the codification of these policies provides greater predictability when preparing for the negotiation process.

What Is New?

While the Final Rule introduces a temporary floor price for eligible biotech manufacturers for IPAY 2029 and IPAY 2030 and finalizes requirements that Part D plans must cover and include negotiated products on Part D formularies, the most impactful new provision may be the closure of the "hyaluronidase loophole."

Previously, CMS established that fixed-combination drugs could qualify as separate qualifying single-source drugs from drugs containing only one of the same active ingredients. However, this guidance created a loophole for products transitioning from intravenous to subcutaneous injections by adding hyaluronidase. The Food and Drug Administration (FDA) treats hyaluronidase as a new active ingredient, thus requiring a separate filing application and meeting the definition of a fixed-combination drug.

The Final Rule specifically addresses this situation, stating that CMS will aggregate products when:

1. The parent drug and fixed-combination drug are held by the same NDA/BLA owner.
2. The added ingredient primarily functions to enable a new route of administration.

Importantly, CMS specifically cites hyaluronidase-containing products as an example of a fixed-combination product that would be treated as a single source drug with its parent product. More broadly, CMS is departing from FDA product distinctions in certain circumstances, which introduces additional complexity into manufacturer portfolio and pipeline strategic planning.

What Does This Mean for Manufacturers?

A Lifecycle Management Strategy Diminished

Historically, developing a follow-on SQ formulation after an IV product with the addition of hyaluronidase has been a successful franchise-level strategy to extend a product’s lifecycle as it approaches loss of exclusivity and introduce an innovative new product, often resulting in operational chair-time savings and patient convenience.

However, CMS now introduces a major obstacle to this strategy. Under the new Final Rule, newer SQ formulations may become subject to negotiation alongside their older IV parent products despite having been on the market for only a few years. As a result, manufacturers may no longer realize the same protection from Medicare negotiation timing that previously existed under the fixed-combination framework nor experience the anticipated return on investment of developing a SQ formulation for the franchise.

A New Biosimilar Dynamic

The policy also creates a new strategic consideration for branded biologic and biosimilar manufacturers.

Although CMS may aggregate IV and SQ products for negotiation purposes, the FDA continues to regulate these products separately, meaning their biosimilar products remain distinct. Under interpretation of CMS's current guidance, biosimilar entry for the parent IV product could remove the Maximum Fair Price (MFP) applicability for both products while leaving the SQ formulation without direct biosimilar competition when its MFP leaves the market.

As a result, manufacturers may need to evaluate not only traditional launch-sequencing considerations but also the relative commercial impact of negotiated pricing versus price erosion from biosimilar competition across an entire franchise. In some cases, the interaction between MFP applicability and biosimilar entry could become as important as the reformulation strategy itself.

How Can Precision AQ Help?

As the Medicare Drug Price Negotiation Program expands, so does the likelihood that manufacturers will face direct and/or indirect exposure to negotiated pricing. Manufacturers developing both IV and SQ biologics will increasingly need to incorporate negotiation eligibility and timing considerations into broader pipeline, portfolio, and lifecycle-management decisions.

For example, manufacturers will need to assess the optimal launch timing for SQ formulations with respect to the IV product’s negotiation eligibility and consider alternate scenarios, such as launching an SQ formulation following IV biosimilar entry when the MFP may no longer apply to either product.

Precision AQ helps manufacturers navigate these questions through a comprehensive, data-driven view of the market that integrates pricing, access, policy, competitive dynamics, and commercialization considerations to inform launch and lifecycle management strategy. To learn more about our end-to-end capabilities, contact our team today.